Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$8.61 – $23.50
100% from low
Borrow rate
0.46%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $311.8M | $229.5M | $108.1M | $111.0M | $156.2M | $152.1M | $125.0M | $118.7M |
| Cost of revenue | $18.5M | $9.5M | $15.8M | $15.8M | $18.7M | $27.0M | $39.2M | $65.4M |
| Gross profit | $293.3M | $220.0M | $92.3M | $95.2M | $137.5M | $125.0M | $85.7M | $53.3M |
| Gross margin | 94.1% | 95.9% | 85.4% | 85.7% | 88.0% | 82.2% | 68.6% | 44.9% |
| R&D | $8.0M | $10.1M | $4.2M | $0 | $0 | $2.8M | $3.8M | $1.7M |
| Operating income | $43.7M | −$194.4M | −$82.2M | $9.4M | $39.4M | −$243.5M | −$24.5M | −$17.2M |
| EBITDA | $213.2M | $97.8M | −$16.3M | $38.8M | $90.2M | $53.2M | $5.1M | $3.1M |
| Net income | $36.9M | −$217.2M | −$28.1M | −$1.3M | $109.6M | −$331.9M | −$21.6M | −$30.4M |
| Net margin | 11.8% | -94.6% | -26.0% | -1.2% | 70.2% | -218.3% | -17.3% | -25.6% |
| EPS (diluted) | 34.50 | -184.35 | -16.05 | -0.45 | 30.45 | -70.05 | -3.45 | -4.74 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $106M | $-1.69 | $-1.71–$-1.67 | 1 |
| 2027 | $115M | $0.38 | $0.37–$0.39 | 1 |
| 2028 | $103M | $1.72 | $1.69–$1.75 | 1 |
| 2029 | $115M | $2.87 | $2.83–$2.91 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ASRT.
No tracked institution reports a position in ASRT as of their last filing.
| Execution date | Ratio |
|---|---|
| 2025-12-26 | 1-for-15reverse |
| 2021-05-18 | 1-for-4reverse |
No one on the platform has traded ASRT yet.
| $31M |
| — |
| LUNGPulmonx Corporation | $1.33 | +6.40% | $56M | — |
| NTRBNutriband Inc. | $3.21 | +4.90% | $39M | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 1.3× sales vs its 0.8× historical median P/S.
Fair value ≈ $15.08 · price $23.50 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
@Akidos1 @PeterDeboner don’t expect immediate reply the firm will need time to look into the books, filings and the history of $ASRT .
View on StockTwits ↗@Akidos1 @PeterDeboner Chuckuk.. “ $ASRT I have lumped in with Monteverdelaw send an email to Juan Monteverde and ask to be included will not commnet on the action as he has a client he is working with but we shoudl be included in the class action. Keep your trading records and I sent hom ownership proof of my 14633. We will see he is a great person with a good record if he feels it is worth pursuing.”
View on StockTwits ↗$ASRT A sad ending to what was once a strong company (DEPOMED).💁🏻♂️👎🙁
View on StockTwits ↗$ASRT Just 3M non temderers means compo will be better for us
View on StockTwits ↗@ATLcitizen @Chuckuk from incompetent $SPPI management to corrupt $ASRT management. It is why it has to go legal. Investors here never stood a chance.
View on StockTwits ↗$ASRT Haha apparently b/c they closed the deal before the expiry date on my $20 June covered calls I get the $23.50 BO price. Pleasant surprise.
View on StockTwits ↗$ASRT pos f u been here since sppi. F isn't real.
View on StockTwits ↗$ASRT I didn't tender my shares. I could not in good conscience agree to this deal . They even had a much better offer they didn't take. It must be that all the perks under the table were much better in this deal
View on StockTwits ↗$ASRT Bit shocking to see no value on the broker account for ASRT
View on StockTwits ↗$ASRT how long does it normally take to get paid for shares I didn’t tender, from what I understand it’s normally 1-3 days…
View on StockTwits ↗$ASRT completed its merger with Zydus Worldwide DMCC, becoming a wholly owned subsidiary of the parent.
View on StockTwits ↗$ASRT Assertio Announces Completion of Merger with Zydus Lifesciences and Fundamental Change and Make-Whole Fundamental Change Relating to its Outstanding 6.50% Convertible Senior Notes due 2027 https://www.businesswire.com/news/home/20260616901266/en/Assertio-Announces-Completion-of-Merger-with-Zydus-Lifesciences-and-Fundamental-Change-and-Make-Whole-Fundamental-Change-Relating-to-its-Outstanding-6.50-Convertible-Senior-Notes-due-2027 Effective today, Assertio common stock has been delisted from the Nasdaq Stock Exchange. Assertio stockholders are receiving $23.50 per share in cash in connection with the acquisition.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.